ARVN - アルビナス (Arvinas Inc.) アルビナス

 ARVNのチャート


 ARVNの企業情報

symbol ARVN
会社名 Arvinas Inc (アルビナス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 アルヴィーナス(Arvinas Inc.)(旧名: Arvinas Holding Co LLC)は開発段階のバイオ医薬品会社である。同社は、疾患を引き起こすタンパク質を分解する治療法の開発と商品化に従事する。同社は病気を引き起こすタンパク質を選択的かつ効率的に分解・除去するために、身体の天然タンパク質処理システムを利用するように設計されたタンパク質分解誘導キメラ分子(PROTACs)を処理する技術プラットフォームを使用する。同社はPROTACプラットフォームを使用して、臓器系および組織における疾患を標的とするタンパク質分解産物候補パイプラインを構築する。同社はまたARV-110とARV-471のリード製品候補を第1相臨床試験に進めることにも注力する。同社は転移性去勢抵抗性前立腺癌(mCRPC)を有する男性にあるARV-110の第 I 相臨床試験、転移性エストロゲン受容体陽性(ER)とHER2陰性乳癌、またはER +陽性乳癌の女性におけるARV-471の第1相臨床試験を開始する予定である。   アルビナスは米国のバイオ薬品会社。がんをはじめとする治療困難な疾患を引き起こすタンパク質を分解し、除去するタンパク質分解剤の開発・研究を行う。特にアンドロゲン受容体およびエストロゲン受容体を含む前立腺がんや乳がんなどのがんに対して有効性のある分解薬の開発に焦点を当てる。本社所在地はコネチカット州ニュ―ヘブン。   Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and "undruggable" targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.
本社所在地 5 Science Park 395 Winchester Avenue New Haven CT 06511 USA
代表者氏名
代表者役職名
電話番号 +1 203-535-1456
設立年月日 41306
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 72人
url www.arvinas.com
nasdaq_url https://www.nasdaq.com/symbol/arvn
adr_tso
EBITDA EBITDA(百万ドル) -24.04163
終値(lastsale) 14.99
時価総額(marketcap) 0
時価総額 時価総額(百万ドル) 951.25580
売上高 売上高(百万ドル) 11.74966
企業価値(EV) 企業価値(EV)(百万ドル) 154.54711
当期純利益 当期純利益(百万ドル) -114.01680
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Arvinas Inc revenues increased from $3.3M to $7.5M. Net loss applicable to common stockholders increased from $12.9M to $98.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 17% to $17.5M (expense) General and administrative increase of 88% to $2.8M (expense).

 ARVNのテクニカル分析


 ARVNのニュース

   Arvinas to Present at Upcoming Investor Conferences  2022/08/31 11:00:00 GlobeNewswire
NEW HAVEN, Conn., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in three upcoming investor conferences:
   Arvinas Stock: Sports Unappealing Risk/Reward Profile (NASDAQ:ARVN)  2022/08/25 04:28:02 Seeking Alpha
Shares of Arvinas have nearly tripled from its IPO price point of $16 back in 2018. See why I still don''t recommend buying ARVN stock.
   Arvinas''s Return on Invested Capital Insights  2022/08/22 13:56:33 Benzinga
According to Benzinga Pro data, Arvinas (NASDAQ: ARVN ) reported Q2 sales of $31.30 million. Earnings fell to a loss of $70.00 million, resulting in a 10.41% decrease from last quarter. In Q1, Arvinas brought in $24.20 million in sales but lost $63.40 million in earnings. What Is Return On Invested Capital? Return on Invested Capital is a measure of yearly pre-tax profit relative to capital invested by a business. Changes in earnings and sales indicate shifts in a company''s ROIC. A higher ROIC is generally representative of successful growth of a company and is a … Full story available on Benzinga.com
   Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment  2022/08/19 15:00:46 Seeking Alpha
Piper Sandler has started coverage of Arvinas (ARVN) with a buy rating saying that Sanofi (SNY) recent discontinuation of amcenestrant for breast cancer will benefit the biotech.The…
   Arvinas Inc. (NASDAQ:ARVN) Lost -1.75% In A Week: What’s Driving The Stock?  2022/08/13 20:00:00 Marketing Sentinel
In last trading session, Arvinas Inc. (NASDAQ:ARVN) saw 0.4 million shares changing hands with its beta currently measuring 2.00. Company’s recent per share price level of $54.46 trading at -$0.08 or -0.15% at ring of the bell on the day assigns it a market valuation of $2.69B. That closing price of ARVN’s stock is at … Arvinas Inc. (NASDAQ:ARVN) Lost -1.75% In A Week: What’s Driving The Stock? Read More »
   Arvinas Inc. (NASDAQ:ARVN)’s 12-Month Price Target Currently Stands At $170.00  2022/04/09 12:30:00 Marketing Sentinel
In last trading session, Arvinas Inc. (NASDAQ:ARVN) saw 0.44 million shares changing hands with its beta currently measuring 1.98. Company’s recent per share price level of $66.42 trading at -$3.74 or -5.33% at ring of the bell on the day assigns it a market valuation of $3.39B. That closing price of ARVN’s stock is at … Arvinas Inc. (NASDAQ:ARVN)’s 12-Month Price Target Currently Stands At $170.00 Read More »
   Expert Ratings For Arvinas  2022/04/06 18:10:52 Benzinga
Arvinas (NASDAQ: ARVN ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 2 1 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 2 2 0 0 0 3M Ago 1 0 0 0 0 These 6 analysts have an average price target of $102.33 versus the current price of Arvinas at $70.83, implying upside. Below is a summary of how these 6 analysts rated Arvinas over the past 3 months. The greater the number of bullish ratings, the more positive analysts … Full story available on Benzinga.com
   Is Arvinas Inc. (NASDAQ: ARVN) A Good Pick For New Investors Now?  2022/04/02 13:30:00 Stocks Register
Arvinas Inc. (NASDAQ:ARVN) shares, rose in value on Friday, 04/01/22, with the stock price up by 4.04% to the previous day’s close as strong demand from buyers drove the stock to $70.02. Actively observing the price movement in the last trading, the stock closed the session at $67.30, falling within a range of $67.40 and … Is Arvinas Inc. (NASDAQ: ARVN) A Good Pick For New Investors Now? Read More »
   Things To Consider Before Buying Arvinas Inc. (NASDAQ: ARVN)  2022/03/12 13:30:00 Stocks Register
Arvinas Inc. (NASDAQ:ARVN) shares, rose in value on Friday, 03/11/22, with the stock price down by -0.53% to the previous day’s close as strong demand from buyers drove the stock to $68.21. Actively observing the price movement in the last trading, the stock closed the session at $68.57, falling within a range of $67.685 and … Things To Consider Before Buying Arvinas Inc. (NASDAQ: ARVN) Read More »
   Where Arvinas Stands With Analysts  2022/03/01 14:09:59 Benzinga
Arvinas (NASDAQ: ARVN ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 2 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 0 0 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, Arvinas has an average price target of $114.0 with a high of $157.00 and a low of $91.00. Below is a summary of how these 4 analysts rated Arvinas over the past 3 months. The greater the number of bullish ratings, the more positive analysts are … Full story available on Benzinga.com
   Arvinas Inc Ranked Among Todays Top Shorts Amid Lower-Than-Expected New Jobs  2021/09/03 17:14:52 Bitcoin Ethereum News
The post Arvinas Inc Ranked Among Todays Top Shorts Amid Lower-Than-Expected New Jobs appeared on BitcoinEthereumNews.com . Getty Thursdays jobless claims impressed. They came in at a pandemic-era low of 340,000 and crushed the forecasted 345,000. Both the S&P and Nasdaq NDAQ hit new records. Friday, however,
   Arvinas to Participate in Upcoming Virtual Investor Conferences  2021/09/01 11:00:00 Intrado Digital Media
NEW HAVEN, Conn., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming virtual investor conferences:
   Arvinas Inc Ranked Among Todays Top Shorts  2021/08/10 18:52:42 Bitcoin Ethereum News
The post Arvinas Inc Ranked Among Todays Top Shorts appeared on BitcoinEthereumNews.com . getty Stocks saw minor gains on Tuesday that were capped by more fears of the Delta variant throwing a serious wrench into the economic recovery and reopening. The Dow Jones
   Arvinas and Insilico Medicine ink R&D collaboration agreement  2021/08/09 13:26:19 Seeking Alpha
   Arvinas EPS misses by $0.17, beats on revenue  2021/08/05 11:55:22 Seeking Alpha

 関連キーワード  (医薬品 米国株 アルビナス ARVN Arvinas Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)